MX2018007818A - Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. - Google Patents

Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.

Info

Publication number
MX2018007818A
MX2018007818A MX2018007818A MX2018007818A MX2018007818A MX 2018007818 A MX2018007818 A MX 2018007818A MX 2018007818 A MX2018007818 A MX 2018007818A MX 2018007818 A MX2018007818 A MX 2018007818A MX 2018007818 A MX2018007818 A MX 2018007818A
Authority
MX
Mexico
Prior art keywords
upk1b
antibodies
methods
novel anti
drug conjugates
Prior art date
Application number
MX2018007818A
Other languages
English (en)
Inventor
A Stull Robert
Fong Sarah
A Williams Samuel
Huang Zhao
Coelho David
Mcknight Kristen
Anderson Wade
Santaguida Marianne
Kim Earl
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of MX2018007818A publication Critical patent/MX2018007818A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Anticuerpos anti-UPK1B novedosos y conjugados de anticuerpo y fármaco, y métodos para el uso de los mencionados anticuerpos y conjugados de anticuerpo y fármaco anti-UPK1B para tratar el cáncer.
MX2018007818A 2015-12-22 2016-12-21 Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. MX2018007818A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562270993P 2015-12-22 2015-12-22
US201662430191P 2016-12-05 2016-12-05
PCT/US2016/068146 WO2017112829A1 (en) 2015-12-22 2016-12-21 Novel anti-upk1b antibodies and methods of use

Publications (1)

Publication Number Publication Date
MX2018007818A true MX2018007818A (es) 2019-07-01

Family

ID=59091208

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007818A MX2018007818A (es) 2015-12-22 2016-12-21 Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.

Country Status (10)

Country Link
US (1) US20190000969A1 (es)
EP (1) EP3393516A1 (es)
JP (1) JP2019511199A (es)
CN (1) CN108472368A (es)
AU (1) AU2016378744A1 (es)
BR (1) BR112018012883A2 (es)
CA (1) CA3009488A1 (es)
MX (1) MX2018007818A (es)
TW (1) TW201800106A (es)
WO (1) WO2017112829A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230090A1 (es) * 2019-09-16 2023-01-16 Opsidio Llc Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos
WO2023239803A1 (en) * 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241703A1 (en) * 2002-08-19 2004-12-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
PT2161283E (pt) * 2003-11-17 2014-08-29 Genentech Inc Composições que compreendem anticorpos contra cd79b conjugados a um agente de inibição do crescimento ou agente citotóxico e métodos para o tratamento de tumor de origem hematopoiética
US8044179B2 (en) * 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
WO2013071175A1 (en) * 2011-11-11 2013-05-16 Alere San Diego, Inc. Devices and methods for detection of panton-valentine leukocidin (pvl)

Also Published As

Publication number Publication date
WO2017112829A1 (en) 2017-06-29
US20190000969A1 (en) 2019-01-03
AU2016378744A1 (en) 2018-07-05
JP2019511199A (ja) 2019-04-25
CN108472368A (zh) 2018-08-31
EP3393516A1 (en) 2018-10-31
BR112018012883A2 (pt) 2019-02-12
CA3009488A1 (en) 2017-06-29
TW201800106A (zh) 2018-01-01

Similar Documents

Publication Publication Date Title
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
TN2015000396A1 (en) Antibody drug conjugates
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
PH12015501846A1 (en) Novel antibody conjugates and uses thereof
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2017011344A (es) Anticuerpos diseñados de sitio específico y métodos de uso.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
PH12017501930A1 (en) Calicheamicin contructs and methods of use
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.